NEW DIABETES OPTIONS FOR IMPROVED OUTCOMES

Course overview

This program will enhance healthcare providers' ability to care for patients taking new injectable classifications of medications for diabetes. Readers will be able to: describe the roles of amylin and the human incretin hormone GLP-1 in regulating blood glucose levels, identify three benefits of pramlintide acetate (Symlin) and exenatide (Byetta) injection therapy, and discuss three interventions to help patients adjust to and properly use pramlintide or exenatide therapy.